Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 801 results for "eisai"

Eisai teams up with Zeria on proton pump inhibitor license agreement
Pharma Letter

Eisai enters into license agreement with Zeria Pharmaceutical

Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. have entered into a license agreement for E3710, a novel proton pump inhibitor, or PPI, discovered and developed in-house by Eisai. Based on this agreement, Eisai will grant Zeria the exclusive ..., 1 hour ago
Zeria to Develop Eisai PPI In Japan PharmaAsia, 6 days ago

13 images for eisai

Pharma Letter, 1 week ago
Drug Discovery and Development, 3 days ago
ABC News 4 Charleston, 3 days ago
I Stock Analyst, 3 days ago
Pharma Letter, 1 week ago
Pharma Letter, 1 week ago
PM 360, 1 week ago
Pharma Letter, 2 weeks ago
Pharma Letter, 2 weeks ago
Pharma Letter, 3 weeks ago

Eisai's Phase III lung cancer study fails to meet primary endpoint

Eisai Co., Ltd., a Japanese pharmaceutical company, has announced that the Phase III study, or Study 302, with its in-house developed anticancer agent, eribulin mesylate, in patients with advanced non-small cell lung cancer, or NSCLC, fails to meet ...
 Individual.com1 day ago Halaven fails to meet primary endpoint in NSCLC  Orthopedics Today2 weeks ago Breast Cancer Drug Eribulin (Halaven) Fails Lung Cancer Trial  PT Community2 weeks ago

Eisai farms out development of shelved cancer drugs

TOKYO -- Eisai has licensed further development of two shelved cancer drug candidates to a pair of bioventures, hoping to leverage their skills to get the compounds back on track and add them to its lineup. Boston Strategics of the U.S. and ...
 Nikkei Asian Review4 days ago TNF Inhibitors for RA: No Link to Breast Cancer  Diabetes Care1 week ago Global Breast Cancer market will grow at 11.61% CAGR over the period 2014-2018.  TransWorldNews3 weeks ago
Pharma Letter

Eisai Submits EU Marketing Authorisation Application for Fycompa(R) (perampanel) as Adjunctive Therapy in People With Uncontrolled Primary Generalised Tonic-Clonic (PGTC) Seizures

/PRNewswire/ -- Eisai has submitted a Marketing Authorisation Application to the European Commission for its first-in-class anti-epileptic drug (AED) Fycompa(R) (perampanel) as an adjunctive treatment of primary generalised tonic-clonic seizures ...
 Individual.com1 week ago Eisai submits marketing authorization to the EU for Fycompa in new seizure indication  Pharma Letter1 week ago

Eisai: demande d'extension d'indications pour Fycompa® (pérampanel) en association dans le traitement des patients présentant des crises generalisées primaires tonico-cloniques (CGPTC) non contrôlées

/PRNewswire/ -- Eisai vient de déposer auprès de la Commission européenne, une demande d'extension des indications de Fycompa ® (pérampanel), « en association dans le traitement des crises primaires généralisées tonico-cloniques (CGPTC) ...
 PR Newswire1 week ago

Eisai solicita autorización para la comercialización de Fycompa® (perampanel) en la UE como terapia adyuvante en personas con crisis tonicoclónicas primarias generalizadas no controladas

/PRNewswire/ -- Eisai ha presentado una solicitud de autorización de comercialización ante la Comisión Europea para su innovador fármaco antiepiléptico Fycompa ® (perampanel) como tratamiento adyuvante de las crisis tonicoclónicas ...
 PR Newswire1 week ago

Eisai beantragt EU-Marktzulassung für Fycompa® (Perampanel) als Zusatztherapie bei primär generalisierten tonisch-klonischen Anfällen

/PRNewswire/ -- Eisai hat bei der Europäischen Arzneimittelagentur (EMA) die Marktzulassung von Fycompa ® (Perampanel), dem ersten Antiepileptikum seiner Art, als Zusatztherapie bei primär generalisierten tonisch-klonischen Anfällen ( primary ...
 PR Newswire1 week ago

EISAI Files Lenvatinib in Europe for People With Radioiodine-Refractory Differentiated Thyroid Cancer

/PRNewswire/ -- FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. MEDIA EMA accepts accelerated review for orphan therapy in hard-to-treat thyroid cancer Eisai announces today that it has filed an application to the European Medicines Agency (EMA) for ...
 Individual.com1 week ago Eisai reicht Lenvatinib in Europa zur Zulassung für die Behandlung des radiojod-refraktären differen...  BioMedReports1 week ago
Pharma Letter

Eisai files for US and EU approval of lenvatinib for hard to treat thyroid cancer

Japanese pharma major Eisai (TYO: 4523) has filed applications with the US Food and Drug Administration and the European Medicines Agency for the use of lenvatinib mesylate in the treatment of patients with progressive radioiodine-refractory ...
 Pharma Letter1 week ago Eisai receives accelerated review from EMA for thyroid cancer drug  Individual.com2 weeks ago EMA approves Eisai's request for accelerated assessment of lenvatinib in thyroid cancer  Pharma Letter3 weeks ago EMA Approves Eisai's Lenvatinib for Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid Cancer  OSIX News3 weeks ago

Belviq Scripts Flat For Arena

Summary Flat scripts demonstrate seasonality and the fact that Eisai is offsetting it. Refills becoming point of focus. Quarter over quarter growth is softening. Sales of Arena Pharmaceuticals (NASDAQ: ARNA ) Belviq were up modestly this week, ...
 Seeking Alpha3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less